Ashley Dombkowski, Ph.D.Dr. Ashley Dombkowski joined MPM Capital in 2000. Before joining MPM, she was a public market investor and Healthcare Equity Analyst covering biotech, medical device, and pharmaceutical stocks for Tiger Management, L.L.C., a diversified hedge fund. Prior to Tiger, Dr. Dombkowski followed the all-cap universe of public medical technology stocks as an Equity Research Associate at Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and a B.A. cum laude and with Departmental Honors from Wellesley College. She is a past or present Director or Board Observer for BioVitrum (Stockhdm: BVT.ST), Enteromedics, Nevro Development, Inc., Neosil, Poniard (NASDAQ: PARD), Peptimmune, Portola Pharmaceuticals, Restore Medical, Rigel (NASDAQ: RIGL) and Tercica (NASDAQ:TRCA). |
|
